Figopitant

DB12122InvestigationalSmall molecule

Figopitant is under investigation in clinical trial NCT02209714 (Safety, Tolerability and Pharmacodynamics After Oral Administration of BIIF 1149 BS in Healthy Male Volunteers).

Mechanism: Pharmacologically active on Substance-P receptor
Curator reviewed
Formula / weight: C₂₇H₃₁F₆N₃O · 527.555 g/mol (avg)
Code names: BIIF-1149 BS

Resolves to

Compound

UNII23X73B9O6QCAS502422-74-4ChEMBLCHEMBL2104927PubChem9914857

Structure

InChIKeyHUTHJVYJUPXHDF-DEOSSOPVSA-NSMILESCN(CCC1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C(=O)[C@@H](N1CCN(CC2CC2)CC1)C1=CC=CC=C1

Targets

P25103TACR1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Figopitant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account